Biophan Receives 'Buy' Rating from Leading European Analyst MIDAS Research Wednesday August 31, 9:05 am ET Research Report Notes Biomedical Company for Innovative Nanotechnology-Based Solutions and Receives $4.20 Price Target
ROCHESTER, N.Y.--(BUSINESS WIRE)--Aug. 31, 2005--Biophan Technologies, Inc. (OTCBB: BIPH - News), a developer of next-generation biomedical technology, has received an unqualified "buy" rating in an independent, third-party research report written by a leading German analyst, MIDAS Research GmbH.
Posts: 1035 | From: Ohio - USA | Registered: Apr 2005
| IP: Logged |
posted
Back now to HOD. Don't understand why people shy from this one? $3 for sure on this upgrade.
Posts: 1035 | From: Ohio - USA | Registered: Apr 2005
| IP: Logged |